Therapeutic blockade of TNF-α has been shown to slow systemic and local bone loss, particularly in inflammatory diseases such as rheumatoid arthritis, supporting the role of inflammatory mediators in bone destruction [25,26]. Here, TNF is linked to rheumatoid arthritis.